G-protein-coupled receptors (GPCRs) have been tractable drug targets for decades with
over one-third of currently marketed drugs targeting GPCRs. Of these, the class A GPCR …

Prognosis in relapsed and refractory acute myeloid leukemia (R/R AML) patients is dismal,
with no satisfactory and standard salvage chemotherapy regimen. We performed a …

Immunomodulatory drugs bind to cereblon (CRBN) to confer differentiated substrate
specificity on the CRL4CRBN E3 ubiquitin ligase. Here we report the identification of a new …

The BCL-2 inhibitor venetoclax has revolutionized the treatment of acute myeloid leukemia
(AML) in patients not benefiting from intensive chemotherapy. Nevertheless, treatment …

Inhibition of the AAA ATPase, p97, was recently shown to be a novel method for targeting
the ubiquitin proteasome system, and CB-5083, a first-in-class inhibitor of p97, has …

Multiple myeloma (MM) is characterized by an immunosuppressive microenvironment that
enables tumor development. One of the mechanisms of immune evasion used by MM cells …

Dysregulated oncogenic serine/threonine kinases play a pathological role in diverse forms
of malignancies, including multiple myeloma (MM), and thus represent potential therapeutic …

Proteomics continues to forge significant strides in the discovery of essential biological
processes, uncovering valuable information on the identity, global protein abundance …

Despite much investment and progress, oncology is still an area with significant unmet
medical needs, with new therapies and more effective use of current therapies needed. The …

Although medical cancer treatment has improved during the past decades, it is difficult to
choose between several first-line treatments supposed to be equally active in the diagnostic …